On August 2, 2024, Yantai Blue Nano Biology Technology Co., Ltd, a subsidiary of Yantai Dongcheng Biochemicals (002675.SZ), received the drug clinical trial approval notice of 177Lu-LNC1011 injection from China National Medical Products Administration (NMPA) and will conduct clinical trials soon.
The company's in-development product, 177Lu-LNC1011 injection, is a targeted radiopharmaceutical drug for the treatment of PSMA-positive advanced prostate cancer patients. According to public data, there is currently only one drug on the global market targeting the same point, Pluvicto, by Novartis. Pluvicto sales in 2023 reached 0.98 billion USD, and in H1 2024 sales reached 0.655 billion USD.